92 related articles for article (PubMed ID: 18161888)
1. Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy.
Halloran CM; Ghaneh P; Connor S; Sutton R; Neoptolemos JP; Raraty MG
Br J Surg; 2008 Apr; 95(4):453-9. PubMed ID: 18161888
[TBL] [Abstract][Full Text] [Related]
2. Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy.
Connor S; Bosonnet L; Alexakis N; Raraty M; Ghaneh P; Sutton R; Neoptolemos JP
Dig Surg; 2005; 22(1-2):80-5. PubMed ID: 15849467
[TBL] [Abstract][Full Text] [Related]
3. Experience with laparoscopic ultrasonography for defining tumour resectability in carcinoma of the pancreatic head and periampullary region.
Taylor AM; Roberts SA; Manson JM
Br J Surg; 2001 Aug; 88(8):1077-83. PubMed ID: 11488793
[TBL] [Abstract][Full Text] [Related]
4. Utility of tumor markers in determining resectability of pancreatic cancer.
Schlieman MG; Ho HS; Bold RJ
Arch Surg; 2003 Sep; 138(9):951-5; discussion 955-6. PubMed ID: 12963650
[TBL] [Abstract][Full Text] [Related]
5. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
6. Staging laparoscopy with laparoscopic ultrasonography: optimizing resectability in hepatobiliary and pancreatic malignancy.
Callery MP; Strasberg SM; Doherty GM; Soper NJ; Norton JA
J Am Coll Surg; 1997 Jul; 185(1):33-9. PubMed ID: 9208958
[TBL] [Abstract][Full Text] [Related]
7. Laparoscopy and laparoscopic ultrasound in the evaluation of pancreatic and periampullary tumours.
Doran HE; Bosonnet L; Connor S; Jones L; Garvey C; Hughes M; Campbell F; Hartley M; Ghaneh P; Neoptolemos JP; Sutton R
Dig Surg; 2004; 21(4):305-13. PubMed ID: 15365229
[TBL] [Abstract][Full Text] [Related]
8. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
[TBL] [Abstract][Full Text] [Related]
9. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma.
Ong SL; Garcea G; Thomasset SC; Mann CD; Neal CP; Abu Amara M; Dennison AR; Berry DP
J Gastrointest Surg; 2008 Jun; 12(6):1068-73. PubMed ID: 18043987
[TBL] [Abstract][Full Text] [Related]
10. CA19-9 as a predictor of resectability in patients with borderline resectable pancreatic cancer.
He Z; Lu H; Du X; Hu W; Zhaoda BT
Hepatogastroenterology; 2013 Jun; 60(124):900-3. PubMed ID: 23321027
[TBL] [Abstract][Full Text] [Related]
11. Combined endoscopic ultrasonography and laparoscopic ultrasonography in the pretherapeutic assessment of resectability in patients with upper gastrointestinal malignancies.
Mortensen MB; Scheel-Hincke JD; Madsen MR; Qvist N; Hovendal C
Scand J Gastroenterol; 1996 Nov; 31(11):1115-9. PubMed ID: 8938906
[TBL] [Abstract][Full Text] [Related]
12. Laparoscopy and laparoscopic ultrasonography in judging the resectability of pancreatic head cancer.
Zhao ZW; He JY; Tan G; Wang HJ; Li KJ
Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):609-11. PubMed ID: 14627530
[TBL] [Abstract][Full Text] [Related]
13. Combined preoperative endoscopic and laparoscopic ultrasonography for prediction of R0 resection in upper gastrointestinal tract cancer.
Mortensen MB; Fristrup CW; Ainsworth AP; Pless T; Nielsen HO; Hovendal C
Br J Surg; 2006 Jun; 93(6):720-5. PubMed ID: 16671064
[TBL] [Abstract][Full Text] [Related]
14. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.
Bloomston M; Bekaii-Saab TS; Kosuri K; Cowgill SM; Melvin WS; Ellison EC; Muscarella P
Pancreas; 2006 Oct; 33(3):246-9. PubMed ID: 17003645
[TBL] [Abstract][Full Text] [Related]
15. Laparoscopic ultrasound: a surgical "must" for second line intra-operative evaluation of pancreatic cancer resectability.
Piccolboni P; Settembre A; Angelini P; Esposito F; Palladino S; Corcione F
G Chir; 2015; 36(1):5-8. PubMed ID: 25827662
[TBL] [Abstract][Full Text] [Related]
16. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer.
Kiliç M; Göçmen E; Tez M; Ertan T; Keskek M; Koç M
Can J Surg; 2006 Aug; 49(4):241-4. PubMed ID: 16948881
[TBL] [Abstract][Full Text] [Related]
17. Is there still a role for laparoscopy combined with laparoscopic ultrasonography in the staging of pancreatic cancer?
Barabino M; Santambrogio R; Pisani Ceretti A; Scalzone R; Montorsi M; Opocher E
Surg Endosc; 2011 Jan; 25(1):160-5. PubMed ID: 20567851
[TBL] [Abstract][Full Text] [Related]
18. Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access GI Monitor assay on the UniCel Dxl 800 Immunoassay System.
Stieber P; Molina R; Gion M; Gressner A; Troalen F; Holdenrieder S; Auge JM; Zancan M; Wycislo M; Jarrige V
Clin Chem Lab Med; 2008; 46(5):600-11. PubMed ID: 18598202
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9.
Forsmark CE; Lambiase L; Vogel SB
Pancreas; 1994 Nov; 9(6):731-4. PubMed ID: 7846016
[TBL] [Abstract][Full Text] [Related]
20. The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer.
Smith RA; Bosonnet L; Ghaneh P; Sutton R; Evans J; Healey P; Garvey C; Hughes M; Raraty M; Campbell F; Neoptolemos JP
Surgery; 2008 May; 143(5):658-66. PubMed ID: 18436014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
